Dr. Kipp Weiskopf, a Valhalla Fellow at the Whitehead Institute, delves into the crucial role of macrophages in cancer therapy. He explains how targeting the CD47/SIRPα axis can promote the destruction of cancer cells. Weiskopf also shares insights on launching spin-off companies aimed at advancing innovative cancer treatments. The conversation explores the complexity of macrophage function within tumors and the emerging therapeutic strategies designed to harness their power for better patient outcomes.